Last Update Time:
13-Mar-2025 16:00:00
ISIN:
INE0O5T01011
Sector:
Healthcare
Symbol:
REMUS
Remus Pharmaceuticals Limited
₹1,953.00
₹-23.45
(-1.19%)
▼
Prev. Close
₹1,976.45
Open
₹1,985.00
Close
₹1,999.80
Range
₹1,855.35 - ₹2,050.65
High
₹2,034.00
Low
₹1,934.00
Ind. Close
₹0.00
VWAP
₹1,972.18
The current stock price of Remus Pharmaceuticals Limited is ₹1,953.00, with a target price range between ₹1,855.35 and ₹2,050.65. The stock has experienced a price change of ₹-23.45 (-1.19%), reflecting recent market volatility.
Today's opening price was ₹1,985.00, while the previous close stood at ₹1,976.45.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Remus Pharmaceuticals Limited Price Chart
Remus Pharmaceuticals Limited Pre Open Market Overview: 13-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 0
- Previous Close Price: 1976.45
- Change: -1,976.45%
- Total Traded Volume: 0
- Total Buy Quantity: 900
- Total Sell Quantity: 1,100
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 0.00 | 0.00 | 0.00 |
| 1,866.00 | 50.00 | 0.00 |
| 1,867.05 | 300.00 | 0.00 |
| 1,870.00 | 50.00 | 0.00 |
| 1,870.05 | 50.00 | 0.00 |
| 1,997.95 | 0.00 | 50.00 |
| 1,998.00 | 0.00 | 100.00 |
| 2,023.00 | 0.00 | 50.00 |
| 2,040.00 | 0.00 | 50.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 900
Total Sell Quantity: 1100
Shareholding Patterns of Remus Pharmaceuticals Limited
Key Trade Statistics of Remus Pharmaceuticals Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.10 |
| Traded Value (₹ Cr.) | 1.93 |
| Total Market Cap (₹ Cr.) | 1,150.71 |
| Free Float Market Cap (₹ Cr.) | 335.37 |
| Impact cost | N/A |
| Quantity Traded | 9,800.00 |
| Deliverable Quantity | 8,900.00 |
| % of Quantity to Traded | 90.82 |
| Security VaR | N/A |
| Index VaR | N/A |
| VaR Margin | 50 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 53.5 |
| Face Value | 10 |
Key Price Statistics of Remus Pharmaceuticals Limited
The 52-week high for Remus Pharmaceuticals Limited was ₹2,834.75, recorded on 03-Sep-2024. On the other hand, the 52-week low stands at ₹1,200.00, with the lowest value recorded on 13-Mar-2024.
The upper band for trading is ₹2,371.70, and the lower band is ₹1,581.20. The price band is 20%.
The stock's daily volatility stands at N/A, while the annualized volatility is N/A. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (03-Sep-2024) | 2,834.75 |
| 52 Week Low (13-Mar-2024) | 1,200.00 |
| Upper Band | 2,371.70 |
| Lower Band | 1,581.20 |
| Price Band (%) | 20 |
| Daily Volatility | - |
| Annualised Volatility | - |
| Tick Size | 0.05 |
Key Securities Statistics of Remus Pharmaceuticals Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 29-May-2023 |
| Adjusted P/E | 30.12 |
| Symbol P/E | 30.12 |
| Index | NIFTY SME EMERGE |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Remus Pharmaceuticals Limited
| Title | Details |
|---|---|
| Board Status | SME |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Remus Pharmaceuticals Limited
| Subject | Date |
|---|---|
| Outcome of Board Meeting | 27-Feb-2025 |
| Updates | 18-Feb-2025 |
| Updates | 13-Jan-2025 |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 10-Jan-2025 |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 09-Jan-2025 |
| Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter | 07-Jan-2025 |
| Reply to Clarification- Financial results | 18-Dec-2024 |
| Updates | 12-Dec-2024 |
Corporate Actions of Remus Pharmaceuticals Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | INTERIM DIVIDEND - RE 1 PER SHARE | 19-Nov-2024 |
| 10 | BONUS 3:1 | 06-Jun-2024 |
| 10 | INTERIM DIVIDEND - RS 4 PER SHARE | 02-May-2024 |
| 10 | INTERIM DIVIDEND - RS 2 PER SHARE | 27-Oct-2023 |
| 10 | DIVIDEND - RS 2 PER SHARE | 15-Sep-2023 |
Board Meetings of Remus Pharmaceuticals Limited
Financial Results of Remus Pharmaceuticals Limited
Company Directory of Remus Pharmaceuticals Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| - | Registered Address | 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, AHMEDABAD - 380054 AHMEDABAD |
AHMEDABAD |
| - | Transfer Agent | 5th Floor, 506 to 508 Amarnath Business Centre-I (ABC ￂ I) Nr. St. Xaviers College Corner off. C.G. Road, Navrangpura , Ahmedabad-380009 AHMEDABAD - 380009 AHMEDABAD |
AHMEDABAD |
Insider Trading of Remus Pharmaceuticals Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Renosen Pharmaceuticals Private Limited | 793648 | Buy |
| 7(2) | Renosen Pharmaceuticals Private Limited | 405466 | Buy |
| 7(2) | Vinodkumar Gandalal Shah | 117250 | Buy |
| 7(2) | Vinodkumar Gandalal Shah | 119250 | Buy |
| 7(2) | Vinodkumar Gandalal Shah | 121250 | Buy |
| 7(2) | Vinodkumar Gandalal Shah | 126250 | Sell |
| 7(2) | Vinodkumar Gandalal Shah | 120178 | Buy |
| 7(2) | ARPIT DEEPAKKUMAR SHAH | 268895 | Buy |
| 7(2) | ARPIT DEEPAKKUMAR SHAH | 1344500 | Buy |
| 7(2) | ARPIT DEEPAKKUMAR SHAH | 1075600 | Buy |
| 7(2) | Renosen Pharmaceuticals Private Limited | 711480 | Buy |
| 7(2) | Renosen Pharmaceuticals Private Limited | 239300 | Buy |
| 7(2) | Renosen Pharmaceuticals Private Limited | 237900 | Buy |
| 7(2) | Renosen Pharmaceuticals Private Limited | 236900 | Buy |
| 7(2) | Renosen Pharmaceuticals Private Limited | 721500 | Buy |
| 7(2) | Renosen Pharmaceuticals Private Limited | 4552800 | Buy |
| 7(2) | ARPIT DEEPAKKUMAR SHAH | 416000 | Buy |
| 7(2) | ARPIT DEEPAKKUMAR SHAH | 419000 | Buy |
| 7(2) | ARPIT DEEPAKKUMAR SHAH | 2092000 | Buy |
| 7(2) | ARPIT DEEPAKKUMAR SHAH | 2090000 | Buy |
Annual Reports of Remus Pharmaceuticals Limited
| Company | From Year | To Year | Att. |
|---|---|---|---|
| Remus Pharmaceuticals Limited | 2023 | 2024 | |
| Remus Pharmaceuticals Limited | 2022 | 2023 |
Investor Complaints of Remus Pharmaceuticals Limited
Event Calendar of Remus Pharmaceuticals Limited
| Purpose | Details |
|---|---|
| Board Meeting Intimation | REMUS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 09-Nov-2024 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2024 and Dividend/Other business. |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended September 30, 2024, interim dividend and other business matters |
| REMUS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 16-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Other business. | Board Meeting Intimation |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2024 and other business matters |
| REMUS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 23-Apr-2024 to consider and approve Dividend/Bonus/Increase in authorised capital/Other business. | Board Meeting Intimation |
| Dividend/Bonus/Other business matters | REMUS : 23-Apr-2024 : The Company has informed the Exchange that a Board meeting to be held on April 22, 2024 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on April 23, 2024, To consider Interim dividend , bonus and other business matters |
| REMUS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 22-Apr-2024 to consider and approve Dividend/Other business. | Board Meeting Intimation |
| Dividend/Other business matters | To consider interim dividend for FY 2024-2025 and other business matters |
| REMUS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 19-Oct-2023 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2023 and Dividend/Other business. | Board Meeting Intimation |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended September 30, 2023, dividend and other business matters |
Share Transfers of Remus Pharmaceuticals Limited
| Company | Period | Reg.7 | Reg.40 | ||
|---|---|---|---|---|---|
| No Share Transfer data available | |||||
Voting Results of Remus Pharmaceuticals Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 20-SEP-2024 | AGM | Adoption of Financial Statements |
| 20-SEP-2024 | AGM | To approve Material Related Party Transactions of the Company |
| 20-SEP-2024 | AGM | Ratification of Related Party Transactions entered during the F.Y. 2023-2024 |
| 20-SEP-2024 | AGM | Revision in Remuneration of Mrs. Anar Swapnil Shah (DIN: 06895297), Whole Time Director of the Company |
| 20-SEP-2024 | AGM | Revision in Remuneration of Ms. Roma Vinodbhai Shah (DIN: 07214632), Whole Time Director of the Company |
| 20-SEP-2024 | AGM | Revision in Remuneration of Mr. Swapnil Jatinbhai Shah (DIN: 05259821), Chairman and Whole Time Director of the Company |
| 20-SEP-2024 | AGM | Revision in Remuneration of Mr. Arpit Deepakkumar Shah (DIN: 07214641), Managing Director of the Company |
| 20-SEP-2024 | AGM | To seek approval under Section 180(1)(a) of the Companies Act, 2013 inter alia for creation of mortgage or charge on the assets, properties or undertaking(s) of the Company |
| 20-SEP-2024 | AGM | To approve the overall Borrowing Limits u/s 180(1)(c) of the Companies Act, 2013 |
| 20-SEP-2024 | AGM | To Appoint the Statutory Auditors and fix their remuneration |
| 20-SEP-2024 | AGM | Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as a director, liable to retire by rotation who has offered himself for re-appointment |
| 21-MAY-2024 | EGM | Increase in Authorised Share Capital of the Company and Alteration of Capital Clause of Memorandum of Association of the Company |
| 21-MAY-2024 | EGM | Approval of issue of Bonus Shares to the Shareholders of the Company |
| 13-MAR-2024 | EGM | Appointment of Statutory Auditor to fill casual vacancy |
| 22-SEP-2023 | AGM | Adoption of Financial Statements for FY 2022-2023 |
| 22-SEP-2023 | AGM | Declaration of dividend for FY 2022-2023 |
| 22-SEP-2023 | AGM | Appointment of Ms. Roma Vinodbhai Shah (DIN: 07214632) as a director, liable to retire by rotation who has offered herself for re-appointment |
FAQs on Remus Pharmaceuticals Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.